Batten Disease — Research Summary
Printed from RareWays (rareways.com.au) on 9 June 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Oncogenic crosstalk between ErbB2, nucleolin and Ras.
Zysman Gal et al. — Cellular signalling (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41672208/
- 2.
Towards understanding memory buffer based continual learning.
Zheng Guodong et al. — Neural networks : the official journal of the International Neural Network Society (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41483569/
- 3.
The 1 -Cys peroxiredoxin, PRDX-6, suppresses an NHR-49-dependent pro-survival response, including the Flavin monooxygenase, FMO-2, that protects against fungal and bacterial infection.
Button Emma L et al. — Redox biology (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41702017/
- 4.
Nucleolin (NCL) is essential for hair cell stereocilia maintenance and auditory function in mice.
Zong Wen et al. — Journal of cell science (23 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41866947/
- 5.
Two thermostable and halotolerant recombinant β-glucosidases from Thermothelomyces thermophilus and their role in lignocellulosic biomass saccharification.
da Rocha Fortes Saraiva Ana Luiza et al. — International journal of biological macromolecules (19 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41864383/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting — Sanford Health
https://clinicaltrials.gov/study/NCT01793168
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Batten Disease
Batten disease (neuronal ceroid lipofuscinosis) is a group of rare and fatal genetic neurological disorders that cause progressive deterioration of vision, seizures, and cognitive and motor decline, often beginning in childhood. The first approved enzyme replacement therapy (cerliponase alfa) targets CLN2 disease and has slowed progression.
Most Recent Research
Overexpression of ErbB receptors, their signaling components and expression of mutant Ras are major contributors to cancer development. Mutant Ras can affect ErbB receptors activation, and the nucleolar protein nucleolin (NCL) can bind and activate ErbB receptors. Previously it was also demonstrated that activated Ras could interact and enhance nucleolin and ErbB1 receptors interaction. Moreover, it was shown that this interaction enhances tumor cell growth. Since ErbB receptors are major oncogenes and ErbB2 is often overexpressed in many cancer types, in the present study we explored the link between ErbB2, Ras and nucleolin oncogenes. Using cell biology and biochemistry methods, we have demonstrated that NCL interaction with ErbB2 is enhanced by H-Ras (12 V) protein. The three proteins colocalize mainly at the plasma membrane, and in other intracellular sites. Using proximity ligation assay, we show that H-Ras (12 V) enhances the formation of ErbB2/NCL complexes, which reside mainly at the plasma membrane but may also be in the cytosol and nucleus. The interaction of the three oncogenes is associated with enhanced ErbB2 phosphorylation as well as ErbB2 mediated downstream signaling to Erk and Akt. Moreover, expression of the three proteins enhances colony formation, anchorage independent growth and cell migration. Thus, activated Ras can enhance the oncogenic effect of ErbB2 and NCL. These findings can be used to develop new ways to treat tumors that overexpress ErbB2/nucleolin and mutant Ras.
Common Questions
What is Batten Disease?
Batten disease (neuronal ceroid lipofuscinosis) is a group of rare and fatal genetic neurological disorders that cause progressive deterioration of vision, seizures, and cognitive and motor decline, often beginning in childhood. The first approved enzyme replacement therapy (cerliponase alfa) targets CLN2 disease and has slowed progression.
How many clinical trials are available for Batten Disease?
RareWays currently indexes 47 clinical trials for Batten Disease, of which 10 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Batten Disease come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Batten Disease.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.